Introduction
Holoprosencephaly (HPE) is the most common malformation of the human forebrain, occurring in one in 250 gestations, although only approximately one in 10 000 liveborn infants present with the condition because of the high proportion of intrauterine lethality (Orioli and Castilla, 2010) . In addition to characteristic structural brain abnormalities, patients typically have accompanying midline facial anomalies, which range from cyclopia or synophthalmia at the most severe end of the spectrum to findings such as hypotelorism and a single central maxillary incisor in less severely affected patients. The causes of HPE are highly heterogeneous. HPE may occur as one component in a syndrome, may be because of cytogenetic anomalies, or may occur because of mutations in over 10 identified genes associated with nonchromosomal, nonsyndromic HPE Solomon et al., 2010) .
HPE is classified into four major types, depending on the degree of severity of brain malformations: alobar (the most severe type), semilobar, lobar, and the more recently described middle interhemispheric variant-type HPE (Hahn and Barnes, 2010) . Patients may also have 'microform' HPE, in which conventional neuroimaging shows no brain anomalies consistent with frank HPE, but patients may have subtle facial features consistent with a midline deficit. Many patients with microform HPE are identified because of the birth of a severely affected relative (Solomon et al., 2010) .
Although the causes of some types of syndromic HPE have been elucidated, others remain less well delineated. Holoprosencephaly-polydactyly syndrome (HPS) is one of the less understood entities, although several lines of enquiry provide interesting hints. Classically diagnosed in patients with a combination of HPE, polydactyly, and apparently normal chromosomes, the criteria for HPS, also called pseudotrisomy 13, have been controversial since the use of the term began (Cohen, 1989a (Cohen, , 1989b (Cohen, , 1989c Hewitt et al., 1989) . Here, we analyze findings in 40 patients with apparent HPS and review the historical and current perspectives on the condition. Our analysis shows key trends in HPS. First, normal chromosomes as a required criterion may not be justified, as cytogenetic abnormalities have been discovered in some patients, pointing to possible genetic causes. Second, along these lines, cytogenetic analysis, including newer microarray and large-scale sequencing techniques, may allow increased molecular understanding of the cause of HPS. Third, clinicians should be aware that patients may have other anomalies (e.g. cardiac and genitourinary), which are highly associated with HPS and should be evaluated for when encountering a patient with HPS.
Diagnostic controversies
There have been difficulties both in defining HPS and in clearly showing its existence as a unified phenotype. The similarity to hydrolethalus syndrome led to the proposal that they are manifestations of the same disorder (Bachman et al., 1990) . Others disagreed, arguing that HPS is a separate entity (Cohen and Gorlin, 1992) . Further delineation of the syndrome led to the suggestion that pseudotrisomy 13 can manifest without polydactyly, an anomaly previously believed essential to the diagnosis (Ramos-Arroyo et al., 1994) . In an attempt to resolve the debate, new criteria were established, taking into account sporadic and familial types of HPS. According to this formulation, a sporadic occurrence would fulfill the diagnostic criteria in the case of a normal karyotype and one of the following: HPE and postaxial polydactyly; HPE and other abnormalities not including polydactyly; or postaxial polydactyly, brain abnormalities such as microcephaly, agenesis of corpus callosum, and/or hydrocephalus, as well as other abnormalities. Patients with familial HPS/ pseudotrisomy 13 would require an affected sibling to have a normal karyotype and the same clinical criteria outlined for sporadic cases would apply (Lurie and Wulfsberg, 1993) .
The controversy grew with the discovery that a normal karyotype, the third classic diagnostic criterion, may not always be evident in patients with HPS. Of the 40 cases described in Table 1 , only 82% have seemingly normal karyotypes. Further, there may be underappreciated cytogenetic anomalies not apparent on conventional chromosome analysis that may account for the presence of HPS (Hewitt et al., 1989; Brown et al., 1993; Chen et al., 1998 Chen et al., , 2005 Chang, 2003; Koolen et al., 2006; Bendavid et al., 2010; Marquis-Nicholson et al., 2011) . As an aggregate, these developments are not surprising, given the growing availability and use of high-density microarrays. Microalterations on chromosome 13 may be the cause of HPS in some. Evidence suggests that the region in question lies in chromosome arm 13q, which includes the locus for ZIC2, a gene frequently mutated in HPE (Hewitt et al., 1989; Brown et al., 1993; Koolen et al., 2006) . Other cytogenetic anomalies in patients with pseudotrisomy 13 include the partial deletion of chromosome 8p and duplication of 5q35.1 (Chen et al., 1998 (Chen et al., , 2005 Chang, 2003; Koolen et al., 2006) . Another study described multiple (21) long contiguous stretches of homozygosity in a patient showing the features of pseudotrisomy 13 (Marquis-Nicholson et al., 2011) .
Theories of causation
The molecular pathogenesis of HPS is poorly understood and is likely complex. Traditionally, HPE is thought to be a result of a loss-of-function mutation, while polydactyly is thought to be a result of a gain-of-function mutation (Clark et al., 2001) . One hypothesis for why both loss-offunction and gain-of-function effects may result from the same pleiotropic mutation is that the response to the signals from the gene(s) responsible for HPS may differ because of varying embryologic patterning of the brain and limbs. Alternatively, the phenotype may result from two or more mutations involving different genes or an as yet undiscovered contiguous gene syndrome, resulting in brain and limb anomalies (Cordero et al., 2008) .
Sonic hedgehog (SHH) is a key molecule in the pathogenesis of HPE and many genes implicated in HPE are tied to the SHH signaling pathway (Solomon et al., 2010) . The presence of HPE because of diverse causes such as Smith-Lemli-Opitz syndrome, maternal alcohol use, and the use of the cholesterol-lowering statin class of medications during pregnancy may all be tied to SHH signaling (Lanoue et al., 1997; Edison and Muenke, 2004; Li et al., 2007) . Further, aberrant SHH signaling is also associated with disorders that manifest polydactyly, including Pallister-Hall syndrome, Greig cephalopolysyndactyly, and isolated postaxial polydactyly (Ming et al., 1998) . Thus, it is highly plausible that hedgehog signaling may be involved in HPS despite the fact that mutations in the SHH gene itself have not yet been identified in patients with HPS.
Nonetheless, it is likely that HPS is a heterogeneous disorder, as shown by theories of HPS inheritance. Among the cases in Table 1 , 28% describe parental consanguinity, leading to the suspicion of autosomal recessive inheritance in some cases (Ramaekers et al., 1989; Bachman et al., 1990; Brown et al., 1993; Ahmet et al., 2006; Marquis-Nicholson et al., 2011) . Eighteen percent of cases were found to have an affected sibling with HPS. However, the possibility of an X-linked or an autosomal dominant mode of inheritance cannot be ruled out (Atkin, 1988; Seller et al., 1993) . Although more males overall (45%) are reported than females (28%), both sexes are significantly represented. Finally, germline mosaicism is well described in isolated HPE, and must not be ignored when discussing possible inheritance patterns (Ramaekers et al.,1989; Solomon et al., 2010) .
Differential diagnosis
With the broader inclusion criteria described above, some cases significantly overlap with other disorders, which may lead to difficulties in establishing a diagnosis. Conditions that share common characteristics with HPS include hydrolethalus syndrome and trisomy 13. Other conditions may have overlapping features, such as Smith-Lemli-Opitz syndrome, Meckel syndrome, and Pallister-Hall syndrome, necessitating a full clinical genetic consultation to help determine whether or not these other diagnoses should be pursued by targeted testing.
Genetic evaluation in a few recent cases of HPS ruled out some of these disorders in at least the tested individuals (Cordero et al., 2008; Zechi-Ceide et al., 2009 ). However, it must be stated that with many of the patients described in our analysis, it is difficult to exclude all overlapping conditions, as not all have had the same clinical diagnostic work-up or extensive molecular testing. In fact, it may well be that patients diagnosed with HPS represent a causally heterogeneous group of patients. As molecular understanding of diseases advances, the aggregate diagnosis of HPS may dissolve into separate conditions. The amount of information was variable for patients, and details are given as specified in the original sources; hence, the terminology may differ slightly between patients so as not to alter data through misinterpretation. ACC, agenesis of the corpus callosum; ASD, atrial septal defect; AV, atrioventricular; HPE, holoprosencephaly; IUGR, intrauterine growth restriction; LCSHs, long contiguous stretches of homozygosity; NS, not specified; TOGV, transposition of the great vessels; VSD, ventricular septal defect. a By conventional chromosome analysis (karyotype) unless otherwise noted.
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Materials and methods
We report on two patients who participated in our National Human Genome Research Institute Institutional Review Board approved protocol on HPE, with appropriate consent obtained from participating families. Samples and available clinical information were sent to our lab from referring clinicians, and sequencing of HPEassociated genes was performed through standard dideoxynucleotide sequencing (methods described in detail in Pineda-Alvarez et al., 2010) .
We analyzed findings in 38 additional previously reported patients with apparent HPS using Pubmed and Medline as search mechanisms with the search terms including 'holoprosencephaly', 'HPE', 'pseudotrisomy', 'pseudotrisomy 13', and 'holoprosencephaly and polydactyly'.
Results

New patient reports
Patient 39 was a 1-year-old male first child of nonconsanguineous parents of western European descent who had an unremarkable family history. Neuroimaging during gestation showed a partial fusion in the rostral basal ganglia believed to represent mild HPE, as well as a lipoma of the corpus callosum. Postnatal MRI confirmed these findings, and indicated that a single maxillary central incisor was not present. Birth measurements showed that head circumference, height, and weight were all below the third centile for gestational age; measurements at 12 months of age showed a weight between the 10th and the 25th centile, body length between the 50th and the 75th centile, and microcephaly, with occipitofrontal head circumference less than the third centile. Facial features were consistent with HPE, with marked midface hypoplasia, a flattened nasal bridge, and a midline cleft lip and palate. Limb anomalies included left upper extremity radial deviation and thumb hypoplasia and evidence of right upper extremity preaxial hexadactyly (status-post surgical correction at the time of examination). Additional anomalies included tetralogy of Fallot, multiple fused and hemivertebrae resulting in scoliosis, hypospadias, and micropenis. The patient showed generalized hypotonia and severe motor delay. Laboratory analysis indicated evidence of diabetes insipidus, but no other endocrinological abnormalities. Karyotype analysis, fluorescence in-situ hybridization for 7q36 and 22q11.2, as well as quantitative cholesterol levels were all normal. Sequence analysis of SHH, ZIC2, SIX3, and TGIF indicated no mutations. An oligonucleotide array CGH (Signature) was not performed.
Patient 40 was diagnosed in utero with HPS. Imaging indicated neuroanatomical anomalies consistent with severe HPE, as well as the presence of a proboscis, polydactyly, cardiac defects, and hemivertebrae. Full autopsy was not performed and further data are not available. Karyotype analysis and oligonucleotide array CGH (Signature) showed no abnormalities. Sequence analysis of SHH, ZIC2, SIX3, TGIF, and GLI2 indicated no mutations.
Combined findings
Patients diagnosed with HPS are presented in Table 1 . The availability of clinical details was variable. Slightly less than 80% of patients were described as having classic HPE and 92% overall were found to have some type of central nervous system defect. Brain anomalies were not recorded in 8% of the patients; however, facial features in these cases were consistent with a diagnosis of HPE. These features include eye abnormalities, such as hypotelorism (70%), cleft lip and/or palate (53%), nose anomalies consistent with HPE (28%), and, separately, proboscis (10%). In patients in whom the HPE type was described, there was a skewing toward severe forms. Thirty-three percent of the patients had alobar, 25% had semilobar, and 5% had lobar HPE.
Polydactyly was described in 80% of patients, whereas 93% had some type of limb abnormality, including polydactyly. At least 95% of patients with polydactyly had postaxial polydactyly. Although organ system defects are not believed to be essential to the diagnosis of HPS, there was a high prevalence of cardiac (58%), genitourinary (35%), gastrointestinal (20%), pulmonary (15%), adrenal (10%), skeletal (10%), and renal (8%) abnormalities (for a more detailed description of the patients, please refer to Table 1 ).
Discussion
Although first described over two decades ago, the definitive diagnosis of HPS remains a challenge. First, the criteria of HPE, polydactyly, and normal chromosomal analysis have served as a guideline for the diagnosis of the syndrome. A broadened list of criteria was subsequently created (Lurie and Wulfsberg, 1993) . Since these criteria were established, more extensive cytogenetic methodologies have become available, leading to the discovery of distinct anomalies found on several chromosomes that may be linked to causes of HPS. Our data suggest that normal chromosomes were found in most but not all cases of HPS. Further, sequencing results from the new patients reported here lend support to the hypothesis that mutations in known and well-characterized HPEassociated genes are not common causes of HPS. With the increased use of newer genomic diagnostic techniques such as high-density microarrays and high-throughput sequencing, smaller regions of genomic variance and individual exonic mutations may be better appreciated, and may possibly lead to an improved understanding of the complex etiology of the condition. It is entirely possible that HPS will remain a unifying clinical diagnosis that can result from many possible genetic and environmental causes, as has been well described for HPE in general (Solomon et al., 2010) . When a clinician considers a diagnosis of HPS, genetic studies on both a clinical and a research basis should be pursued to further understand the condition, as well as to improve the management of these patients.
Second, our data highlight a high prevalence of a variety of visceral anomalies, most significantly involving the cardiac and genitourinary systems, in patients with HPS. This prevalence of visceral anomalies in HPS appears overall higher than in HPE more generally. In a recent and impressively large study describing a cohort of over 600 European patients with HPE, 27% were found to have visceral anomalies (Mercier et al., 2011) . Although perhaps not essential for the identification of HPS, clinicians should be aware of the presence of such characteristics in these patients. These findings may also point to potential causes. For example, the neuroanatomical anomalies of HPE can naturally lead to a variety of endocrinologic disturbances, but adrenal cortical development appears to be directly linked to the SHH signaling pathway (Ching and Vilain, 2009; King et al., 2009; Huang et al., 2010) , implying a role for this pathway in at least some patients.
Finally, along these lines, we suggest the following for work-up of a patient in whom a clinician is considering a diagnosis of HPS: detailed clinical exam by a geneticist to assess for polydactyly and other anomalies, with further studies as indicated; neuroimaging (MRI is preferred) to establish the presence and type of HPE as well as other central nervous system anomalies; echocardiogram; renal ultrasound; conventional karyotype, with reflex microarray if the karyotype is negative; further targeted genetic testing if other conditions in the differential diagnosis appear likely; as well as consideration of research participation.
